Zoetis(NYSE) ZTS

Zoetis Inc. makes medicines for pets and livestock. It helps veterinarians and farmers keep animals healthy. These products treat and prevent many types of illness.

Care for Every Species

• Companion Animal Products: Medicines, vaccines, and diagnostic tests for dogs, cats, and horses.
• Livestock Products: Health solutions for cattle, swine, poultry, fish, and sheep.
• Diagnostic Solutions: Portable analysis systems, point-of-care devices, and reference laboratory services.
• Medicated Feed Additives: Health-enhancing additives for livestock, although the company divested a major portion of this portfolio in 2026.

Moving the Needle

• Divested the medicated feed additive portfolio and certain water-soluble products in 2026.
• Launched Lenivia and Portela long-acting pain treatments in international markets during 2026.
• Eliminated the one-month financial reporting lag for international subsidiaries in 2026 to align fiscal years.
• Completed a $2.0 billion private offering of convertible senior notes in Dec. 18, 2025.

What Sets Zoetis Apart

The company directly markets products in 45 countries and maintains sales in over 100 nations. It relies on a large technical sales force and deep research capabilities to maintain its industry leadership.

By the Numbers

• Revenue was $4.7 billion in the six-month period ended June 30, 2026, up 1% year over year.
• Net income was $1.3 billion in the six-month period ended June 30, 2026, down 3% year over year.
• International segment revenue hit $2.3 billion in the six-month period ended June 30, 2026, up 12% year over year.
• U.S. segment revenue was $2.4 billion in the six-month period ended June 30, 2026, down 7% year over year.

Future Foundations

Zoetis has evolved from a subsidiary into a global leader in animal health innovation. Its focus on companion animal medicine and international markets has created a diversified business model.